Table 3.

Select new FDA-approved anti-tuberculosis drugs and antivirals on the market in the USA since year 2017

Drug class	Names and notes	Indications	Side effects	Comments
Antiviral protein inhibitor	Tecovirimat	Small pox in adults and children	Headache in healthy volunteers; hypoglycemia when combined with repaglinide	Available through Strategic national Stockpile. Unknown efficacy in humans
Endonuclease inhibitor	Baloxavir marboxil	Influenza up to 48 h in duration in patients 12 years of age or older	No significant side effects described	Single-dose completes the course of treatment, avoid co administration with antacids, laxatives, or oral supplements
Non-nucleoside reverse transcriptase inhibitor	Doravirine	Combination therapy for HIV infection	Uncommon; immune reconstitution inflammatory syndrome	Do not co-administer strong cytochrome P450 enzyme inducers
Monoclonal anti MDR HIV antibody	Ibalizumab-uiyk	MDR HIV infection	Diarrhea, rash; immune reconstitution inflammatory syndrome
Anti-hepatitis C combination drug	Glecaprevir and pibrentasvir	Hepatitis C infection	Reactivation of hepatitis B that can result in fulminant hepatitis; worsening liver failure;	Contraindicated in patients with severe liver impairment; avoid co-administering strong cytochrome P450 enzyme inducers
Anti-hepatitis C combination drug	Sofosbuvir/velpatasvir/voxilaprevir	Hepatitis C infection	Reactivation of hepatitis B that can result in fulminant hepatitis, case reports of severe bradycardia when amiodarone is co-administered; headache	Not recommended in patients with moderate to severe hepatic impairment; do not co administer rifampin;